Clinical Chemistry · 2017 · 57 citations · 49 references
PharmacyPharmacokineticsPharmacologyBioavailabilityNoncompartmental AnalysisPopulation PharmacokineticsCannabinoid PharmacologyDrug DispositionBlood Cannabinoid AnalysisCannabinoid DetectionCannabis Drug TestingOral Fluid Cannabinoid TestingOral Fluid Cannabis TestingOral Fluid CollectionOral Fluid IntakeThc Blood Concentration
Abstract BACKGROUND Roadside oral fluid (OF) Δ9-tetrahydrocannabinol (THC) detection indicates recent cannabis intake. OF and blood THC pharmacokinetic data are limited and there are no on-site OF screening performance evaluations after controlled edible cannabis. CONTENT We reviewed OF and blood cannabinoid pharmacokinetics and performance evaluations of the Draeger DrugTest®5000 (DT5000) and Alere™ DDS®2 (DDS2) on-site OF screening devices. We also present data from a controlled oral cannabis administration session. SUMMARY OF THC maximum concentrations (Cmax) were similar in frequent as compared to occasional smokers, while blood THC Cmax were higher in frequent [mean (range) 17.7 (8.0–36.1) μg/L] smokers compared to occasional [8.2 (3.2–14.3) μg/L] smokers. Minor cannabinoids Δ9-tetrahydrocannabivarin and cannabigerol were never detected in blood, and not in OF by 5 or 8 h, respectively, with 0.3 μg/L cutoffs. Recommended performance (analytical sensitivity, specificity, and efficiency) criteria for screening devices of ≥80% are difficult to meet when maximizing true positive (TP) results with confirmation cutoffs below the screening cutoff. TPs were greatest with OF confirmation cutoffs of THC ≥1 and ≥2 μg/L, but analytical sensitivities were <80% due to false negative tests arising from confirmation cutoffs below the DT5000 and DDS2 screening cutoffs; all criteria were >80% with an OF THC ≥5 μg/L cutoff. Performance criteria also were >80% with a blood THC ≥5 μg/L confirmation cutoff; however, positive OF screening results might not confirm due to the time required to collect blood after a crash or police stop. OF confirmation is recommended for roadside OF screening. ClinicalTrials.gov identification number: NCT02177513
49
Toking, Vaping, and Eating for Health or Fun
Gillian L. Schauer, Brian A. King, Rebecca Bunnell et al. · American Journal of Preventive Medicine · 2015 · 339 citations · Full text
Comparison of the subjective effects of Δ 9 -tetrahydrocannabinol and marijuana in humans
S.R. Wachtel, Mahmoud A. ElSohly, Samir A. Ross et al. · Psychopharmacology · 2002 · 211 citations
Medicine, Pharmacology, Psychology +12